Key result
Continuous insulin infusion treatment for 14-16 days significantly reduced arachidonic acid-stimulated platelet TXA2 synthesis from 276 to 199 ng iTXB2/ml (P<0.05) in type I diabetic patients.
Why the study?
Does continuous insulin infusion treatment improve platelet aggregation and TXA2 synthesis in type I diabetic patients?
Does continuous insulin infusion treatment improve platelet aggregation and TXA2 synthesis in type I diabetic patients?
Absolute Event Rate: 199% vs 276%
p-value: p=<0.05
No takes yet. Share an insight, caveat, or question.
May reduce platelet reactivity in type 1 diabetes; hypothesis-generating and should not yet change practice.
Mayfield et al. (1985) studied Type I diabetes mellitus (n=16). Continuous insulin infusion treatment vs. Baseline (before treatment) was evaluated on Platelet synthesis of TXA2 (measured as iTXB2 at 30 s post-arachidonic acid) (p=<0.05). Continuous insulin infusion treatment for 14-16 days significantly reduced arachidonic acid-stimulated platelet TXA2 synthesis from 276 to 199 ng iTXB2/ml (P<0.05) in type I diabetic patients.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: